Alembic Pharma arm inks pact with Curon to develop cancer treatment drug in Greater China
Posted by
www.biotecnika.org
As per the agreement, Rhizen will receive an undisclosed upfront cash
payment and is eligible to receive additional development and
commercial milestone payments with an overall deal value of USD 149.5
million plus double-digit royalties.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/alembic-pharma-arm-inks-pact-with-curon-to-develop-cancer-treatment-drug-in-greater-china/articleshow/78633244.cms
Subscribe to:
Post Comments (Atom)
Post a Comment